Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
PYPD
SELLREMOVEPolyPid Ltd. · Healthcare · Israel · $92M · Avg Vol: $746K/d
A micro-cap healthcare play with low quality metrics (Q: 22) and no clear path to near-term profitability or structural pricing power.
COMPANY DESCRIPTION
PolyPid Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted, localized therapeutics. The company's competitive moat is its proprietary PLEX (Polymer-Lipid Encapsulation Matrix) technology, which enables the controlled, prolonged release of drugs directly at the surgical site. Its lead product candidate targets the prevention of surgical site infections, positioning the company as a niche player in post-operative care.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — |
| EPS | -2.10 | -1.47 | -4.91 | -2.09 | — |
| Shares | 19.2M | 19.2M | 10.2M | 18.2M | -5.1% |
| Debt | 13.7M | 11.8M | 9.6M | 2.8M | -41.2% |
| Equity | 5.8M | -2.1M | 7.7M | 11.0M | 23.5% |
| Op CF | -34.3M | -17.2M | -22.0M | -27.9M | — |
| Inv CF | 16.6M | 3.8M | -0.3M | -6.7M | — |
| Fin CF | 16.4M | 10.0M | 32.4M | 25.4M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PYPD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| PYPD | PolyPid Ltd.(you) | $92M | 24 | SELL |
| ENLV | Enlivex Ltd. | $146M | 18 | STRONG SELL |
| ENTX | Entera Bio Ltd. | $70M | 4 | STRONG SELL |
| SLGL | Sol-Gel Technologies Ltd. | $246M | 39 | HOLD |
| DRTS | Alpha Tau Medical Ltd. | $890M | 36 | HOLD |
| CGEN | Compugen Ltd. | $196M | 93 | STRONG BUY |
| NNOX | Nano-X Imaging Ltd. | $112M | 8 | STRONG SELL |
| BVC.L | BATM Advanced Communications Ltd. | $69M | 56 | HOLD |
| 1696.HK | Sisram Medical Ltd | $134M | 64 | HOLD |
| BWAY | BrainsWay Ltd. | $585M | 83 | STRONG BUY |
Peer medians: ROE 6.5% · P/E 9.9x · Gross margin 36.8%